Table 4.
Differences in healthcare resource utilisation between different Interferon Beta formulations
| Avonex® | Betaferon® | Extavia® | Plegridy® | Rebif® | |
|---|---|---|---|---|---|
| Hospital admissions | 3.24% | 2.86% | 5.80% | 2.77% | 2.96 |
| OR | 0.97 | 1.03 | 3.80 | 0.72 | reference |
| 95%CI | 0.41, 2.25 | 0.37, 2.85 | 1.27, 11.85 | 0.16, 3.11 | |
| p-value | 0.95 | 0.94 | 0.02 | 0.66 | |
| Emergency admissions | 1.94% | 2.3% | 4.35% | 2.54% | 1.98% |
| OR | 0.96 | 1.07 | 2.60 | 2.08 | reference |
| 95%CI | 0.40, 2.27 | 0.43, 2.69 | 1.17, 4.17 | 1.08, 4.63 | |
| p-value | 0.93 | 0.87 | < 0.01 | 0.04 | |
| MS-related admissions | 38.51% | 53.74% | 31.88% | 37.06% | 34.90% |
| OR | 1.41 | 4.77 | 1.22 | 1.67 | reference |
| 95%CI | 1.07, 2.04 | 2.74, 8.31 | 0.48, 3.15 | 1.12, 3.01 | |
| p-value | 0.03 | < 0.01 | 0.67 | 0.04 |
Table shows percent of patients with hospital admissions, emergency admissions, and MS-related admissions for different Interferon Beta formulations (out of all individuals on treatment with each Interferon Beta formulation). OR, 95%CI, and p-values are reported from mixed effect logistic regression models adjusted by age, sex, and treatment duration (Rebif® was used as reference in the statistical models)